A citation-based method for searching scientific literature

Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice Labianca, Monica Ganzinelli, Rosaria Gallucci, Nicoletta Zilembo, Gabriella Francesca Greco, Valter Torri, Filippo de Braud, Marina C Garassino. Eur J Cancer 2021
Times Cited: 8







List of co-cited articles
57 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Gregory J Riely, Joel W Neal, D Ross Camidge, Alexander I Spira, Zofia Piotrowska, Daniel B Costa, Anne S Tsao, Jyoti D Patel, Shirish M Gadgeel, Lyudmila Bazhenova,[...]. Cancer Discov 2021
34
87

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, Natasha J Sng, Antonio R Lucena-Araujo, Wee-Lee Yeo, Mark S Huberman, David W Cohen, Sohei Nakayama, Kota Ishioka,[...]. Sci Transl Med 2013
284
62

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal,[...]. Nat Med 2018
175
50

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Maria E Arcila, Khedoudja Nafa, Jamie E Chaft, Natasha Rekhtman, Christopher Lau, Boris A Reva, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Mol Cancer Ther 2013
229
50


Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
Francois Gonzalvez, Sylvie Vincent, Theresa E Baker, Alexandra E Gould, Shuai Li, Scott D Wardwell, Sara Nadworny, Yaoyu Ning, Sen Zhang, Wei-Sheng Huang,[...]. Cancer Discov 2021
21
50

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Bob T Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai-Yan Tu, Mackenzie L Myers, Chongrui Xu,[...]. Cancer Discov 2020
40
37

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese Pisegna, Alissa Poteete, Huiying Sun,[...]. Cancer Cell 2019
48
37

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang, C Rivard, G Gao, T L Ng, M M Tu,[...]. Ann Oncol 2019
78
37

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou,[...]. Lancet Oncol 2015
465
37

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
37

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
37

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
264
37


The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal.
Valerio Gristina, Umberto Malapelle, Antonio Galvano, Pasquale Pisapia, Francesco Pepe, Christian Rolfo, Silvia Tortorici, Viviana Bazan, Giancarlo Troncone, Antonio Russo. Cancer Treat Rev 2020
34
37

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
Chee Khoon Lee, Johnathan Man, Sally Lord, Matthew Links, Val Gebski, Tony Mok, James Chih-Hsin Yang. J Thorac Oncol 2017
413
37

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
37

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
37

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
37

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, Seo-Yoon Jeong, Jae-Hwan Kim, Kyoung-Ho Pyo, Chae-Won Park, Seong Gu Heo, Mi Ran Yun, Sangbin Lim,[...]. Cancer Discov 2020
46
37

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
144
25

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
Russell W Madison, Sumati V Gupta, Yasir Y Elamin, Douglas I Lin, Sumanta K Pal, Andrea Necchi, Vincent A Miller, Jeffrey S Ross, Jon H Chung, Brian M Alexander,[...]. BJU Int 2020
8
25

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Keunchil Park, Eric B Haura, Natasha B Leighl, Paul Mitchell, Catherine A Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee,[...]. J Clin Oncol 2021
11
25

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
B van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, M S Paats, K Monkhorst, D A M Heideman, M Groves, T Radonic, E F Smit, E Schuuring,[...]. Lung Cancer 2020
28
25

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
106
25

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J Millar, Kathryn Packman,[...]. Mol Cancer Ther 2020
14
25

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Geoffrey R Oxnard, Peter C Lo, Mizuki Nishino, Suzanne E Dahlberg, Neal I Lindeman, Mohit Butaney, David M Jackman, Bruce E Johnson, Pasi A Jänne. J Thorac Oncol 2013
157
25

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang W Shao,[...]. Clin Cancer Res 2018
191
25

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
J Naidoo, C S Sima, K Rodriguez, N Busby, K Nafa, M Ladanyi, G J Riely, M G Kris, M E Arcila, H A Yu. Cancer 2015
103
25

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Sheri L Moores, Mark L Chiu, Barbara S Bushey, Kristen Chevalier, Leopoldo Luistro, Keri Dorn, Randall J Brezski, Peter Haytko, Thomas Kelly, Sheng-Jiun Wu,[...]. Cancer Res 2016
90
25

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W Zhu, Misako Nagasaka, Yan Yang,[...]. Lung Cancer 2020
19
25

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter.
Pei Jye Voon, Dana Wai Yi Tsui, Nitzan Rosenfeld, Tan Min Chin. Mol Cancer Ther 2013
25
25

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Takeshi Shimamura, Hongbin Ji, Yuko Minami, Roman K Thomas, April M Lowell, Kinjal Shah, Heidi Greulich, Karen A Glatt, Matthew Meyerson, Geoffrey I Shapiro,[...]. Cancer Res 2006
107
25

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang. J Thorac Oncol 2020
6
33

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I Shapiro, Dejan Juric, David I Quinn, Victor Moreno, Bernard Doger,[...]. Nature 2018
316
25

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, S Peters, E Dansin, M Früh, M Pless,[...]. Ann Oncol 2016
167
25

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
Samanthi A Perera, Danan Li, Takeshi Shimamura, Maria G Raso, Hongbin Ji, Liang Chen, Christa L Borgman, Sara Zaghlul, Kathleyn A Brandstetter, Shigeto Kubo,[...]. Proc Natl Acad Sci U S A 2009
122
25

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Julien Mazières, Solange Peters, Benoit Lepage, Alexis B Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, Thierry Urban,[...]. J Clin Oncol 2013
385
25

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
25

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
Simon Vyse, Paul H Huang. Signal Transduct Target Ther 2019
98
25

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
Jonathan W Riess, David R Gandara, Garrett M Frampton, Russell Madison, Nir Peled, Jose A Bufill, Grace K Dy, Sai-Hong Ignatius Ou, Philip J Stephens, John D McPherson,[...]. J Thorac Oncol 2018
59
25

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
Andrés F Cardona, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Helano C Freitas, Sara T Granados, Omar Castillo, George Oblitas, Luis Corrales, Christian D Castro, Alejandro Ruiz-Patiño,[...]. Lung Cancer 2018
20
25

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima,[...]. Lancet Oncol 2010
25

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Noura J Choudhury, Adam J Schoenfeld, Jessica Flynn, Christina J Falcon, Hira Rizvi, Charles M Rudin, Mark G Kris, Maria E Arcila, Glenn Heller, Helena A Yu,[...]. Clin Cancer Res 2021
9
25


Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Ken Uchibori, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Nat Commun 2017
176
25


Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
M Beau-Faller, N Prim, A-M Ruppert, I Nanni-Metéllus, R Lacave, L Lacroix, F Escande, S Lizard, J-L Pretet, I Rouquette,[...]. Ann Oncol 2014
176
25

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
577
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.